NMTC vs. SGHT, ZJYL, STIM, LNSR, ECOR, PDEX, EDAP, FONR, TELA, and MLSS
Should you be buying NeuroOne Medical Technologies stock or one of its competitors? The main competitors of NeuroOne Medical Technologies include Sight Sciences (SGHT), Jin Medical International (ZJYL), Neuronetics (STIM), LENSAR (LNSR), electroCore (ECOR), Pro-Dex (PDEX), Edap Tms (EDAP), FONAR (FONR), TELA Bio (TELA), and Milestone Scientific (MLSS). These companies are all part of the "medical equipment" industry.
NeuroOne Medical Technologies vs.
NeuroOne Medical Technologies (NASDAQ:NMTC) and Sight Sciences (NASDAQ:SGHT) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, profitability, risk, community ranking, valuation, earnings, analyst recommendations and media sentiment.
In the previous week, Sight Sciences had 2 more articles in the media than NeuroOne Medical Technologies. MarketBeat recorded 3 mentions for Sight Sciences and 1 mentions for NeuroOne Medical Technologies. Sight Sciences' average media sentiment score of 0.51 beat NeuroOne Medical Technologies' score of 0.00 indicating that Sight Sciences is being referred to more favorably in the news media.
16.1% of NeuroOne Medical Technologies shares are held by institutional investors. Comparatively, 55.5% of Sight Sciences shares are held by institutional investors. 8.9% of NeuroOne Medical Technologies shares are held by insiders. Comparatively, 28.9% of Sight Sciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Sight Sciences has a net margin of -63.30% compared to NeuroOne Medical Technologies' net margin of -82.17%. Sight Sciences' return on equity of -47.28% beat NeuroOne Medical Technologies' return on equity.
NeuroOne Medical Technologies has higher earnings, but lower revenue than Sight Sciences. NeuroOne Medical Technologies is trading at a lower price-to-earnings ratio than Sight Sciences, indicating that it is currently the more affordable of the two stocks.
Sight Sciences has a consensus price target of $4.68, indicating a potential upside of 85.11%. Given Sight Sciences' stronger consensus rating and higher probable upside, analysts clearly believe Sight Sciences is more favorable than NeuroOne Medical Technologies.
NeuroOne Medical Technologies received 44 more outperform votes than Sight Sciences when rated by MarketBeat users. Likewise, 71.59% of users gave NeuroOne Medical Technologies an outperform vote while only 31.15% of users gave Sight Sciences an outperform vote.
NeuroOne Medical Technologies has a beta of 0.48, meaning that its share price is 52% less volatile than the S&P 500. Comparatively, Sight Sciences has a beta of 2.52, meaning that its share price is 152% more volatile than the S&P 500.
Summary
Sight Sciences beats NeuroOne Medical Technologies on 13 of the 18 factors compared between the two stocks.
Get NeuroOne Medical Technologies News Delivered to You Automatically
Sign up to receive the latest news and ratings for NMTC and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
NeuroOne Medical Technologies Competitors List
Related Companies and Tools
This page (NASDAQ:NMTC) was last updated on 2/22/2025 by MarketBeat.com Staff
Free NMTC Stock Alerts